HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis.

Abstract
α-Mannosidosis is a rare lysosomal storage disease with accumulation of undegraded mannosyl-linked oligosaccharides in cells throughout the body, most notably in the CNS. This leads to a broad spectrum of neurological manifestations, including progressive intellectual impairment, disturbed motor functions, and cerebellar atrophy. To develop therapeutic outcome measures for enzyme replacement therapy that could be used for human patients, a gene knockout model of α-mannosidosis in mice was analyzed for CNS pathology and motor deficits. In the cerebellar molecular layer, α-mannosidosis mice display clusters of activated Bergman glia, infiltration of phagocytic macrophages, and accumulation of free cholesterol and gangliosides (GM1), notably in regions lacking Purkinje cells. α-Mannosidosis brain lysates also displayed increased expression of Lamp1 and hyperglycosylation of the cholesterol binding protein NPC2. Detailed assessment of motor function revealed age-dependent gait defects in the mice that resemble the disturbed motor function in human patients. Short-term enzyme replacement therapy partially reversed the observed cerebellar pathology with fewer activated macrophages and astrocytes but unchanged levels of hyperglycosylated NPC2, gangliosides, and cholesterol. The present study demonstrates cerebellar alterations in α-mannosidosis mice that relate to the motor deficits and pathological changes seen in human patients and can be used as therapeutic outcome measures.
AuthorsMarkus Damme, Stijn Stroobants, Steven U Walkley, Renate Lüllmann-Rauch, Rudi D'Hooge, Jens Fogh, Paul Saftig, Torben Lübke, Judith Blanz
JournalJournal of neuropathology and experimental neurology (J Neuropathol Exp Neurol) Vol. 70 Issue 1 Pg. 83-94 (Jan 2011) ISSN: 1554-6578 [Electronic] England
PMID21157375 (Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • alpha-Mannosidase
Topics
  • Animals
  • CHO Cells
  • Cerebellum (enzymology, pathology, physiopathology)
  • Cricetinae
  • Cricetulus
  • Disease Models, Animal
  • Enzyme Replacement Therapy (methods)
  • Gene Targeting
  • Humans
  • Lameness, Animal (drug therapy, enzymology, genetics)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Neurologic Mutants
  • Treatment Outcome
  • alpha-Mannosidase (deficiency, genetics)
  • alpha-Mannosidosis (drug therapy, enzymology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: